Osmotic device containing a venlafaxine salt and a salt having an ion in common
View Patent ↗The osmotic devices of the present invention include a single core comprising a salt of a drug and an osmotic salt, wherein the drug salt and the osmotic salt have a common ion. The release rate of the active drug is reduced, and the release profile of the active drug is modified, from a first order release profile to a zero order, pseudo-zero order, or sigmoidal release profile, by increasing the amount of the sodium chloride in the core of the device. In one embodiment the sodium chloride is used to modify a controlled release profile to a delayed and controlled release profile.
1. An osmotic device comprising:
a unitary core comprising venlafaxine salt, one or more excipients and osmotic salt wherein the weight ratio of venlafaxine salt to osmotic salt ranges from 0.35:1 to 150:1; and
a semipermeable membrane surrounding the core and having one or more passageways there through;
wherein the drug salt is released through the one or more passageways according to a sigmoidal controlled release profile when the osmotic device is exposed to an aqueous environment of use, wherein the drug salt and osmotic salt have a common ion, and wherein release of venlafaxine salt is delayed for a period of 30 min to 10 hours, said delay being caused by the osmotic salt in the core.
2. The osmotic device of claim 1 , wherein the venlafaxine salt is a venlafaxine mineral acid salt, and the osmotic salt is an alkali metal salt.
3. The osmotic device of claim 2 , wherein the alkali metal salt is sodium chloride and the mineral acid is hydrogen chloride.
4. The osmotic device of claim 1 , wherein the venlafaxine salt is a venlafaxine organic acid salt, and the osmotic salt is an organic salt.
5. The osmotic device of claim 1 , wherein the venlafaxine salt is venlafaxine succinate and the osmotic salt is sodium succinate or magnesium succinate.
6. The osmotic device of claim 1 , wherein the venlafaxine salt is venlafaxine fumarate and the osmotic salt is sodium fumarate.
7. The osmotic device of claim 1 , wherein the venlafaxine salt is venlafaxine citrate and the osmotic salt is sodium citrate.
8. The osmotic device of claim 1 , wherein the venlafaxine salt is venlafaxine butyrate and the osmotic salt is sodium butyrate.
9. An osmotic device comprising:
a) a unitary core comprising a mixture of venlafaxine hydrochloride, one or more excipients and sodium chloride, wherein crystals of the sodium chloride are not coated with cellulose acetate butyrate, wherein the weight ratio of venlafaxine hydrochloride to sodium chloride is 0.35:1 to 150:1; and
b) a semipermeable membrane surrounding the core and having one or more passageways there through;
wherein the drug salt is released through the one or more passageways according to a sigmoidal controlled release profile when the osmotic device is exposed to an aqueous environment of use, wherein the drug is not pseudoephedrine or oxybutynin, and wherein release of venlafaxine hydrochloride is delayed for a period of 30 min to 10 hours, said delay being caused by the sodium chloride in the core.
10. An osmotic device comprising:
a) a unitary core comprising venlafaxine hydrochloride, one or more excipients, and sodium chloride, wherein the weight ratio of venlafaxine hydrochloride to sodium chloride is 0.35:1 to 150:1; and
b) a semipermeable membrane surrounding the core and having one or more passageways there through, the membrane having a controlled porosity or permeability adapted to cooperate with the sodium chloride to provide a predetermined release profile for venlafaxine hydrochloride;
wherein the sodium chloride is present in an amount sufficient such that venlafaxine hydrochloride is released through the one or more passageways according to a sigmoidal controlled release profile when the osmotic device is exposed to an aqueous environment of use, and wherein release of venlafaxine hydrochloride is delayed for a period of 30 min to 10 hours, said delay being caused by sodium chloride in the core.
11. The osmotic device of claim 10 , further comprising a second active drug in the core.
12. The osmotic device of claim 11 , wherein the second active drug is amantadine.
13. The osmotic device of claim 1 , wherein the venlafaxine salt is present at 37.5 mg, 75 mg or 150 mg strength.
14. The osmotic device of claim 1 , wherein the osmotic salt is present at 10%, 15%, 20%, 30%, or 52% wt. of the core.
15. The osmotic device of claim 1 , wherein the semipermeable membrane comprises cellulose ester and a plasticizer.
16. The osmotic device of claim 15 , wherein the cellulose ester is selected from the group consisting of cellulose acylate, cellulose diacylate, cellulose triacylate, cellulose acetate, cellulose diacetate, cellulose triacetate, mono, di and tricellulose alkanylates, mono, di and tricellulose aroylates.
17. The osmotic device of claim 15 , wherein the plasticizer is selected from low molecular weight polymers, oligomers, copolymers, oils, small organic molecules, low molecular weight polyols having aliphatic hydroxyls, ester-type plasticizers, glycol ethers, poly(propylene glycol), multi-block polymers, single block polymers, low molecular weight poly(ethylene glycol), citrate ester-type plasticizers, triacetin, propylene glycol and glycerin.
18. The osmotic device of claim 15 , wherein the cellulose ester is cellulose acetate (CA) and the plasticizer is poly(ethylene glycol).
19. The osmotic device of claim 18 , wherein the ratio of cellulose acetate to poly(ethylene glycol) ranges from 50-99% by weight of CA:50-1% by weight of PEG, and about 95% by weight of CA:about 5% by weight of PEG.
20. The osmotic device of claim 1 comprising:
a unitary core comprising: venlafaxine hydrochloride present at 37.5 mg, 75 mg or 150 mg strength; sodium chloride present at 10% to 52% wt. of the core; binder present at 10-18 mg; and plasticizer present at 2-100 mg;
a membrane surrounding the core, having at least one passageway of 0.2-0.8 mm there through, and comprising two cellulose esters and a plasticizer.
21. The osmotic device of claim 20 comprising:
a unitary core comprising: venlafaxine hydrochloride present at 37.5 mg, 75 mg or 150 mg strength; sodium chloride present at 10% to 52% wt. of the core; diluent; binder present at 10-18 mg; low molecular weight plasticizer present at 2-15 mg; and higher molecular weight plasticizer present at 0-85 mg;
a membrane surrounding the core, having at least one passageway of 0.2-0.8 mm there through, and comprising two cellulose esters and a plasticizer.
22. The osmotic device of claim 21 comprising:
a unitary core comprising: venlafaxine hydrochloride present at 37.5 mg, 75 mg or 150 mg strength; sodium chloride present at 10% to 52% wt, of the core; diluent; binder present at 10-18 mg; low molecular weight plasticizer present at 2-15 mg; and higher molecular weight plasticizer present at 0-85 mg;
a membrane surrounding the core, having at least one passageway of 0.2-0.8 mm there through, and comprising two cellulose esters and a plasticizer, wherein: a) the first cellulose ester is present at 11-18.5 mg, the second cellulose ester is present at 6.5-12 mg, and the plasticizer is present at 1-3 mg, and the membrane weighs 24-28.14 mg; or b) the first cellulose ester is present at 4.5-8 mg, the second cellulose ester is present at 15-20 mg, and the plasticizer is present at 1-3 mg, and the membrane weighs 21.5 to 27.9 mg.
23. The osmotic device of claim 22 comprising:
a unitary core comprising: venlafaxine hydrochloride present at 37.5 mg, 75 mg or 150 mg strength; sodium chloride present at 10% to 52% wt. of the core; diluent present at 0-150 mg; binder present at 10-18 mg; low molecular weight plasticizer present at 2-15 mg; higher molecular weight plasticizer present at 0-85 mg; glidant present at 0.2-5 mg; and lubricant present at 1-7 mg;
a membrane surrounding the core, having at least one passageway of 0.2-0.8 mm there through, and comprising two cellulose esters and a plasticizer, wherein: a) the first cellulose ester is present at 11-18.5 mg, the second cellulose ester is present at 6.5-12 mg, and the plasticizer is present at 1-3 mg, and the membrane weighs 24-28.14 mg; or b) the first cellulose ester is present at 4.5-8 mg, the second cellulose ester is present at 15-20 mg, and the plasticizer is present at 1-3 mg, and the membrane weighs 21.5 to 27.9 mg.
24. The osmotic device of claim 23 , wherein:
the binder is selected from the group consisting of poly(vinylpyrrolidone), povidone, sodium carboxymethylcellulose, alginic acid, poly(ethylene glycol), guar gum, polysaccharide, bentonite clay, sugar, poloxamer, collagen, albumin, gelatin, poly(propylene glycol), and poly(ethylene oxide);
the cellulose ester is selected from the group consisting of cellulose acetate, cellulose acylate, cellulose fatty acid ester, and cellulose acetate phthalate;
the plasticizer is selected from the group consisting of poly(ethylene glycol), low molecular weight polymer, citrate ester, triacetin, propylene glycol, glycerin, sorbitol lactate, ethyl lactate, butyl lactate, ethyl glycolate, and dibutylsebacate;
the lubricant is selected from the group consisting of calcium stearate, magnesium stearate, mineral oil, stearic acid, and zinc stearate;
the diluent is selected from the group consisting of microcrystalline cellulose, lactose, sucrose, mannitol, cellulose, starch, sorbitol, dibasic calcium phosphate, and calcium carbonate; and
the glidant is selected from the group consisting of colloidal silica, cornstarch, talc, calcium silicate, magnesium silicate, colloidal silicon, and silicon hydrogel.
25. A method of treating or preventing a disorder, disease or symptom responsive to venlafaxine therapy, the method comprising the step of administering to a subject an osmotic device according to any one of claims 1 , 9 , 10 , 20 - 22 or 23 , wherein one or more of the side effects observed in the subject are of lesser occunence or severity than the side effects observed in the same subject administered another dosage form comprising substantially the same amount of venlafaxine hydrochloride but releasing the venlafaxine hydrochloride according to a different release profile.
26. The method of claim 25 , wherein the side effects are nausea, constipation, anorexia, vomits, flatulence, somnolence, dry mouth, dizziness, insomnia, nervousness, abnormal dreams, tremor, bluned vision, abnormal ejaculation, impotence, sexual dysfuntion, sustained hypertension, hot flashes, asthenia, and/or sweating.
27. A method of treating or preventing a disorder, disease or symptom responsive to venlafaxine therapy, the method comprising the step of administering to a subject an osmotic device according to claims 1 , 9 , 10 , 20 - 22 or 23 , wherein the intervals of the upward titration observed in the subject are shorter than the intervals of the upward titration observed in the same subject administered another dosage form comprising substantially the same amount of venlafaxine hydrochloride but releasing the venlafaxine hydrochloride according to a different release profile.
28. A method of treating or preventing a disorder, disease or symptom responsive to venlafaxine therapy, the method comprising the step of administering to a subject an osmotic device according to claim 1 , 9 , 10 , 20 - 22 or 23 , wherein the peak-trough fluctuations of plasma concentrations observed in the subject is lower than the peak-trough fluctuations of plasma concentrations observed in the same subject administered another dosage form comprising substantially the same amount of venlafaxine but releasing the venlafaxine according to a different release profile.
29. A method of reducing drug-drug interactions in a subject comprising the step of administering to the subject a first dosage form comprising a first drug and an osmotic device according to claim 1 , 9 , 10 , 20 - 22 or 23 instead of administering to the subject the first dosage form comprising the first drug and another dosage form comprising substantially the same amount of venlafaxine but releasing the venlafaxine according to a different release profile, thereby obtaining in the subject a venlafaxine release profile that is less conducive to producing drug-drug interactions between the first drug and venlafaxine
30. A method for providing in a subject a therapeutic plasma concentration of VFX over a 24-hour period with reduced nausea and emesis, the method comprising administering to the subject an osmotic device according to claim 1 , 9 , 10 , 20 - 22 or 23 that provides a peak plasma level of venlafaxine during the period of from about 9 to about 28 hours after administration.